Pliant Therapeutics (NASDAQ:PLRX) Price Target Cut to $1.50 by Analysts at Citigroup
Pliant Therapeutics (NASDAQ:PLRX – Free Report) had its price objective lowered by Citigroup from $4.00 to $1.50 in a report released on Tuesday morning,Benzinga reports. The brokerage currently has a neutral rating on the stock. PLRX has been the subject of several other reports. Canaccord Genuity Group reissued a “hold” rating and issued a $4.00 […]
Pliant Therapeutics (NASDAQ:PLRX – Free Report) had its price objective lowered by Citigroup from $4.00 to $1.50 in a report released on Tuesday morning,Benzinga reports. The brokerage currently has a neutral rating on the stock. PLRX has been the subject of several other reports. Canaccord Genuity Group reissued a “hold” rating and issued a $4.00 […]
